IBC's Vaccine Development & Production Summit continues to bring you new data on ways to achieve your development and production goals. This year, hear the challenges and triumphs of product developers who continue to advance their innovations to combat emerging and infectious diseases.
From the development of new cell lines to novel formulation strategies to process design and manufacturing considerations, IBC's Vaccine Development & Production Summit gives you access to applicable knowledge that you can readily apply to your own vaccine development portfolio.
Manufacturing A Recombinant Measles Virus For Treating Patients With Multiple Myeloma Mark J. Federspiel, Ph.D., Director, Viral Vector Production Laboratory, Mayo Clinic Comprehensive Cancer Center
Vaccine Adjuvant Science Leonard Friedland, MD, Vice President, Scientific Affairs and Public Health Vaccines, GlaxoSmithKline
Designing the Next Generation of Vaccine Adjuvants Derek T. O'Hagan, Ph.D., Vice President, Global Head of Vaccine Chemistry and Formulation Research, Novartis Vaccines
Development of a Malaria Transmission Blocking Vaccine as a Chemically Conjugated Nanoparticle David L. Narum, Ph.D., Head of Process Development, Laboratory of Malaria Immunology and Vaccinology, NIH
Challenges Experienced During the Approval Process of a Novel Recombinant Influenza Vaccine Penny Post, Ph.D., Director of Regulatory, Protein Sciences Corp.
Analytical Characterization of CHIKV VLP as a Vaccine Candidate Sha Ha, Ph.D., Director, Merck
Exclusive Interview with Manon M.J. Cox, President and CEO, Protein Sciences Corporation
Protein Sciences Corporation developed the world's first recombinant, highly purified, egg-free influenza vaccine, Flublok®, which the FDA regards as a technological advance in the manufacturing of an influenza vaccine.
Listen to a 7 minute exclusive interview with Manon M.J. Cox.: